IP Library Granted Patent US 11,072,631
Granted Patent B2
US 11,072,631 · App. 15/762,781 · Granted Jul 27, 2021

Methods and intermediates for the preparation bile acid derivatives

Inventors: Kevin Schaab (Spring Valley, CA); Paul E. Whitley (Florence, SC); Flavio Chavez Lopez (Florence, SC); Kayla R. Iorga (Dalzell, SC)
Assignee: Intercept Pharmaceuticals, Inc.
C07J31/006C07J9/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,072,631
App. No.
15/762,781
Granted
Jul 27, 2021
Kind
B2
Abstract

The present invention relates to methods and novel intermediates useful in the preparation of a compound of formula (A) or a pharmaceutically acceptable salt thereof, comprising converting the aldehyde of a compound of formula (B) with a reducing agent to prepare a compound of formula (C) and converting the compound of formula (C) with a sulfating reagent to prepare a compound of formula (A). An objective of the present invention is to provide methods of preparing bile acid derivatives and novel intermediates. A use of the methods and intermediates described relates to the synthesis of bile acid derivatives which activate both FXR and TGR5.

Claims (28)

1. A method of preparing a sodium salt of a compound of formula (A)

wherein R 1 is H or C 1 -C 6 alkyl, the method comprising the steps of:

(a) dissolving an ammonium salt of the compound of formula (A) in an aqueous solution; and

(b) passing the aqueous solution through a cation-exchange resin, wherein the cation-exchange resin is Na + form

wherein the compound of formula (A) is prepared through the steps of

converting the aldehyde of a compound of formula (B) with a reducing agent to prepare a compound of formula (C)

wherein R 2 is a protecting group;

converting the compound of formula (C) with a sulfating reagent to prepare a compound of formula (D)

or a pharmaceutically acceptable salt thereof; and

deprotecting the C-3 hydroxyl of the compound of formula (D) to form a compound of formula (A).

2. The method of claim 1 , further comprising lyophilization of the sodium salt of the compound of formula (A).

3. The method of claim 2 , further comprising purifying the sodium salt of the compound of formula (A) by reverse phase chromatography.

4. The method of claim 1 , wherein R 1 is C 1 -C 4 alkyl, and the C-7 hydroxyl is in the alpha-orientation.

5. The method of claim 1 , wherein R 2 is —C(O)C 1 -C 4 alkyl.

6. The method of claim 1 , wherein the reducing reagent in step (a) is selected from NaBH 4 , NaCNBH 3 , LiBH 4 , (i-Bu 2 AlH) 2 , and an organoborane.

7. The method of claim 1 , wherein the sulfating reagent in step (b) is selected from sulfur trioxide pyridine, sulfur trioxide trimethylamine, sulfur trioxide triethylamine, sulfur trioxide N,N-dimethylformamide, poly(4-vinylpyridine) sulfur trioxide, chlorosulfonic acid, oleum, and sulfamic acid.

8. The method of claim 1 , wherein R 2 is acetyl and the deprotection in step (c) is performed under acidic conditions.

9. The method of claim 1 , further comprising converting a compound of formula (E) to prepare the compound of formula (B):

10. The method of claim 9 , further comprising protecting the C-3 hydroxyl of a compound of formula (F) to prepare the compound of formula (E):

11. The method of claim 10 , further comprising converting a compound of formula (G) to prepare the compound of formula (F):

12. The method of claim 11 , further comprising converting a compound of formula (H) to prepare the compound of formula (G):

wherein R 3 is C 1 -C 6 alkyl.

13. The method of claim 12 , further comprising converting a compound of formula (I) to afford the compound of formula (H):

wherein R 3 is C 1 -C 6 alkyl.

14. The method of claim 1 , wherein the compound of formula (A) is compound 7,

wherein the method further comprises converting compound 7B to compound 7C:

and

further converting compound 7C to compound 7.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Jan 4, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 066662/0210 →
CHANGE OF ADDRESS Recorded Aug 22, 2022
From: INTERCEPT PHARMACEUTICALS, INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 061297/0990 →
SECURITY INTEREST Recorded Aug 18, 2021
From: INTERCEPT PHARMACEUTICALS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 057650/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: WHITLEY, PAUL E.; LOPEZ, FLAVIO CHAVEZ; IORGA, KAYLA R.
To: PATHEON API SERVICES INC.
Reel/Frame 054138/0223 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2020
From: PATHEON API SERVICES INC.
To: INTERCEPT PHARMACEUTICALS, INC.
Reel/Frame 054138/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2019
From: SCHAAB, KEVIN
To: INTERCEPT PHARMACEUTICALS, INC
Reel/Frame 047963/0480 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2018
From: WHITLEY, PAUL E; LOPEZ, FLAVIO CHAVEZ; IORGA, KAYLA R.
To: PATHEON API SERVICES, INC.
Reel/Frame 047078/0970 →
Continuity (2)
Provisional Application 62222943 · Sep 24, 2015
Related Publication 20200239515A1 · Jul 30, 2020